Onchilles Named Itself After NEU-002. AACR Will See Why.
Onchilles Pharma presents new NEU-002 preclinical data at AACR 2026 for its systemic ELANE pathway therapy.
Category Voyager Articles
Pheast’s First Phase 1a Data Drops. The Weissman Lab Is Back.
Pheast Therapeutics delivers first Phase 1a data for PHST001, a CD24-blocking antibody from the Weissman lab.
Allegria Gets €1.3M to Chase Celldex in Chronic Urticaria
Allegria Therapeutics gets a small grant to enter a chronic urticaria race Celldex is about to lap.
StarkAge’s ADC Targets Senescent Cells, Not Cancer Cells
StarkAge Therapeutics is bringing a senolytic ADC targeting DPP4/CD26 to AACR 2026, aiming to clear senescent cells in the tumor microenvironment.
Antifungals Are Boring. They’re Also About to Save a Lot of Lives.
Elion Therapeutics started a Phase 2 trial of turletricin, a next-generation polyene antifungal designed to keep amphotericin's power without the kidney toxicity.
Daiichi Wants Better Delivery. They Just Bet on a Nano Motor.
Interna Therapeutics signed a research collaboration with Daiichi Sankyo to evaluate its Molecular Nano Motor delivery platform for targeted therapeutics.
A “Mirror-Image” RNA Drug Just Got Glioblastoma Data Into Nature
TME Pharma published GLORIA trial data in Nature Communications showing NOX-A12 plus radiation and bevacizumab improved survival in MGMT-unmethylated GBM.
Janux Has Three PSMA Drugs Now. The Backup Just Got Its First Patient.
Janux Therapeutics dosed the first patient in JANX014, a double-masked PSMA T cell engager that backs up its lead JANX007 in mCRPC.
A 488-Amino-Acid CRISPR That Fits Inside an AAV
Metagenomi published a compact Cas12f CRISPR variant small enough for single-AAV delivery, with editing activity that rivals larger systems.
A Chinese Biotech Just Filed the World’s First LILRB4 T Cell Engager
Mabwell's 6MW5311 became the first LILRB4/CD3 bispecific T cell engager to reach clinical submission anywhere in the world.